FDA Advisory Committee Recommends Medtronic, Inc. (Jobs)'s Endeavor(R) Drug-Eluting Stent for Approval

MINNEAPOLIS--(BUSINESS WIRE)--The last bullet point following, “Highlights from the clinical studies of the Endeavor stent include the following findings:" should read, “In the ENDEAVOR IV clinical trial at nine months, the overall stent thrombosis rate was 0.8 percent (protocol defined), and there were no stent thrombosis observed after six months.” sted “In the ENDEAVOR IV clinical trial at nine months, the overall stent thrombosis rate was 0.5 percent (protocol defined), and there were no stent thrombosis observed after six months.”